Clinical Research Trial Enrollment
Pharmaceutical Formulation of LSD for Depression
This study is investigating the effects of investigational MM120, a form of LSD (lysergic d–tartrate), on Major Depressive Disorder(MDD). The sponsor of the study is Mind Medicine Inc. It features a study drug designated as a “breakthrough therapy”* by the FDA due to its promising past results. This study is conducted under strict medical supervision and participation is completely legal.
FYI: We’re also enrolling for a clinical trial investigating MM120 for Generalized Anxiety Disorder. Click here to learn more.
The first step to participating in this study is to complete a short pre-eligibility survey. Our team will review your responses and contact you with the next steps.
You may qualify if:
🗓️ You are between 18 and 74 years old | 🌧️ You’ve been diagnosed with depression by a licensed professional | 💊 You are currently taking an antidepressant | 📍 You can attend in-person visits at our La Jolla clinic.
Compensation is provided for your time and travel.
Step 1
Complete a short eligibility survey
Step 2
Complete a screening call with our study recruiter
Step 3
If eligible and consenting, you will be enrolled in the study!
* When the FDA grants Breakthrough Therapy Designation to an investigational drug, it means the drug has shown preliminary clinical evidence that it may offer a significant improvement over existing treatments for a serious or life-threatening condition. This designation helps expedite development and review, providing the drug sponsor with increased FDA guidance and priority review to bring the treatment to patients faster.
If you know someone struggling with depression or anxiety who may be interested in this opportunity, please share this with them.
Principal Investigator
Professor Emeritus, UCSD | Founder, Kadima Neuropsychiatry
This study is done at Kadima Neuropsychiatry Institute in La Jolla, CA
Clinical Trial Summary: